Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia

Haemophilia. 2023 Jul;29(4):1155-1159. doi: 10.1111/hae.14814. Epub 2023 Jun 20.

Authors

Xiaohong Sun¹, Wei Liu², Binyu Luo³, Dongwei Ma³, Hindu Kalluru⁴, Yangmei Zhou³, Jin Li³, Ao Peng¹, Yuwang Liu¹, Xin Tong³, Lei Sun³, John Teeter⁵, Sangeeta Raje⁶, Renchi Yang²

Affiliations

¹ Development China, Pfizer Investment Co. Ltd., Beijing, China.
² Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
³ Pfizer (China) R&D Center, Shanghai, China.
⁴ Pfizer Healthcare India Private Ltd., Chennai, India.
⁵ Pfizer Inc, Groton, Connecticut, USA.
⁶ Pfizer Inc, Collegeville, Pennsylvania, USA.

PMID: 37339017
DOI: 10.1111/hae.14814

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Dose-Response Relationship, Drug
Double-Blind Method
East Asian People
Healthy Volunteers
Hemophilia A* / drug therapy
Humans

Substances

marstacimab
Antibodies, Monoclonal, Humanized

Grants and funding

Pfizer